section name header

Pronunciation

eth-oh-SUX-i-mide

Classifications

Therapeutic Classification: anticonvulsants

Indications

REMS


Action

  • Elevates the seizure threshold.
  • Suppresses abnormal wave and spike activity associated with absence (petit mal) seizures.
Therapeutic effects:
  • Prevention of absence (petit mal) seizures.

Pharmacokinetics

Absorption: Rapidly and completely absorbed from the GI tract following oral administration.

Distribution: Freely distributed throughout body water.

Metabolism/Excretion: Mostly metabolized by the liver. 10% excreted unchanged by the kidneys.

Half-Life: 50–60 hr (adults); 30 hr (children).

Time/Action Profile

(anticonvulsant activity)

ROUTEONSETPEAKDURATION
POhr–daysdaysdays





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: STEVENS-JOHNSON SYNDROME, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), hirsutism, rash, urticaria

EENT: myopia

GI: abdominal pain, anorexia, cramping, diarrhea, hiccups, nausea, vomiting, weight loss

GU: pink/brown discoloration of urine, vaginal bleeding

Hemat: agranulocytosis, eosinophilia, immune thrombocytopenia, leukopenia, pancytopenia

Neuro: FREQUENCY OF TONIC-CLONIC (GRAND MAL) SEIZURES, SUICIDAL THOUGHTS, ataxia, dizziness, drowsiness, euphoria, fatigue, headache, hyperactivity, irritability, psychiatric disturbances

Misc: ALLERGIC REACTION, systemic lupus erythematosus

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Zarontin